Warning letter
CJ Labs, Inc. [ARCHIVED]: warning letter of Nov 1, 2011
FDA warning letter 206776 · Florida District Office
Key facts
| Reference number | 206776 |
|---|---|
| Company | CJ Labs, Inc. [ARCHIVED] |
| Subject | CGMP in Manufacturing, Packaging, Labeling or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Nov 1, 2011 |
| Posted date | Nov 1, 2011 |
| Issuing office | Florida District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111, 111.83, 111.105, 111.260, 111.403, 111.23(b), 111.27(a), 111.35(b)(1)(iii), 111.35(b)(6), 111.70(b), 111.70(e), 111.75(a)(2)(ii) and 20 more |
| Inspection city | Miami |
| Inspection ZIP | 33186 |
| Inspection start date | May 25, 2011 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: